Medication Reconciliation - NAPLEX

1. A 50-year-old female (72 kg) with hypothyroidism presents for medication reconciliation. She takes levothyroxine 125 mcg by mouth every morning. She recently started OTC calcium carbonate 1000 mg daily and ferrous sulfate 325 mg daily for "bone health and energy," taken together with levothyroxine at breakfast. Medical history: hypothyroidism, iron deficiency. Allergies: none. Labs: thyroid-stimulating hormone (TSH) 9.8 mIU/L (high; normal ~0.4–4.0), SCr 0.8 mg/dL. Which action should the pharmacist take to optimize this patient's medication regimen?
   Answer: Advise separating levothyroxine from calcium and iron by at least 4 hours to improve absorption This question tests the identification of administration-related interactions affecting drug absorption during reconciliation. The key patient-specific factor is the concurrent timing of levothyroxine with calcium and iron, reducing its absorption and leading to elevated TSH. Advising separation by at least 4 hours is the best choice to optimize thyroid control. Stopping levothyroxine is incorrect; taking with calcium does not improve tolerability; increasing calcium does not address TSH. A transferable clinical pearl is to take levothyroxine on an empty stomach, separated from interacting supplements. Best practices include counseling on timing and correlating with thyroid labs.
2. A 70-year-old female (62 kg) is admitted for confusion and nausea. Home medications brought in a bag include: digoxin 0.25 mg by mouth daily, metoprolol tartrate 50 mg by mouth twice daily, furosemide 20 mg by mouth daily, and a new prescription from a cardiologist for digoxin 0.125 mg by mouth daily started 1 week ago. Medical history: atrial fibrillation, heart failure. Allergies: none. Labs: SCr 1.7 mg/dL, potassium 3.2 mEq/L (low), digoxin level 2.4 ng/mL (high; typical 0.5–2.0). Which medication discrepancy should the pharmacist address first?
   Answer: Identify duplicate digoxin prescriptions and hold digoxin pending prescriber evaluation due to toxicity risk This question tests the detection of duplicate prescriptions for narrow therapeutic index drugs during admission reconciliation. The key patient-specific factor is the two digoxin prescriptions (0.25 mg and 0.125 mg), leading to elevated levels and toxicity symptoms like nausea and confusion. Identifying the duplication and holding digoxin pending evaluation is the best choice to prevent further toxicity. Continuing both risks overdose; stopping metoprolol is suboptimal as it is not the cause; increasing furosemide does not address digoxin toxicity. A transferable clinical pearl is to monitor digoxin levels closely in renal impairment and hypokalemia, which potentiate toxicity. Best practices include reconciling medication bags against histories and correlating with symptoms and labs.
3. A 67-year-old male (77 kg) with type 2 diabetes is seen after a specialist visit. The endocrinologist started semaglutide 0.25 mg subcutaneously weekly (to titrate) and instructed the patient to stop sitagliptin. The primary care medication list still shows sitagliptin 100 mg by mouth daily, and the patient has been taking both. Current meds: metformin 1000 mg twice daily, sitagliptin 100 mg daily, semaglutide 0.25 mg weekly, and atorvastatin 20 mg nightly. Allergies: none. Labs: A1c 8.2%, SCr 1.0 mg/dL. What is the most significant duplication in therapy present?
   Answer: Sitagliptin and semaglutide (incretin-based therapies) used together without added benefit This question evaluates the identification of therapeutic duplication in diabetes management during medication reconciliation, focusing on incretin-based therapies. The key patient-specific factor is the concurrent use of sitagliptin and semaglutide, despite the endocrinologist's instruction to discontinue sitagliptin, leading to overlapping mechanisms without additional glycemic benefit. Identifying sitagliptin and semaglutide as the most significant duplication is the best choice because both target the incretin pathway—sitagliptin inhibits DPP-4 to increase endogenous GLP-1, while semaglutide directly agonizes GLP-1 receptors—potentially increasing side effects like gastrointestinal upset without improved efficacy. Metformin and semaglutide together is not a duplication, as they have complementary mechanisms and are commonly combined for better A1c control; atorvastatin and semaglutide have no overlapping therapeutic effects, with atorvastatin addressing dyslipidemia. Metformin and sitagliptin together is a standard combination without duplication issues, unlike the incretin overlap. A transferable clinical pearl is to review specialist notes during reconciliation to ensure alignment with the full medication list. Decision frameworks should prioritize de-prescribing redundant therapies to minimize adverse effects and optimize patient adherence.
4. A 55-year-old male (weight 95 kg) comes to the pharmacy after a dental procedure and asks what he can take for pain. His current medications: lisinopril 40 mg once daily, chlorthalidone 25 mg once daily, and naproxen 500 mg twice daily that he has been taking for chronic back pain; he also takes OTC ibuprofen 200 mg tablets "sometimes on top of naproxen" and a daily multivitamin. Labs from last week: serum creatinine 1.6 mg/dL (elevated; reference 0.6–1.3), potassium 4.7 mEq/L, alanine aminotransferase 19 U/L. Medical history: hypertension, chronic back pain, chronic kidney disease stage 3. Allergies: none. What is the most concerning interaction in this patient's regimen?
   Answer: Naproxen plus ibuprofen causing additive nonsteroidal anti-inflammatory drug toxicity and increased kidney injury risk This question evaluates recognition of nephrotoxic drug combinations during medication reconciliation in a patient with chronic kidney disease. The patient has CKD stage 3 (elevated creatinine 1.6 mg/dL) and is taking both naproxen regularly and ibuprofen intermittently, representing dangerous NSAID duplication that significantly increases risk of acute kidney injury. Naproxen plus ibuprofen causing additive NSAID toxicity and increased kidney injury risk (option B) is the most concerning interaction because dual NSAID use provides no additional benefit but dramatically increases risk of renal vasoconstriction, acute kidney injury, GI bleeding, and cardiovascular events, especially dangerous in a patient with pre-existing CKD. Lisinopril plus chlorthalidone (option A) does not cause hyperkalemia - thiazide diuretics cause hypokalemia. Multivitamin plus chlorthalidone (option C) does not cause hypoglycemia. Lisinopril plus multivitamin (option D) does not cause hepatotoxicity. During medication reconciliation for CKD patients, identifying all NSAID use (prescription and OTC) is critical as these agents are contraindicated in advanced CKD and should be used cautiously if at all in earlier stages - acetaminophen or non-pharmacologic approaches are preferred for pain management.
5. A 67-year-old male (weight 82 kg) presents to the emergency department for dizziness and near-syncope. He brings a pillbox but is unsure of the names; his pharmacy profile shows metoprolol succinate 50 mg once daily, while his cardiologist note from last week lists metoprolol tartrate 50 mg twice daily; the patient states he is taking "one metoprolol in the morning and one at night." Other medications: lisinopril 20 mg once daily, hydrochlorothiazide 25 mg once daily, atorvastatin 40 mg nightly, aspirin 81 mg once daily, and OTC diphenhydramine 25 mg at bedtime as needed. Vitals show heart rate 44 beats/min; labs: serum creatinine 1.0 mg/dL, potassium 3.9 mEq/L, alanine aminotransferase 22 U/L. Medical history: hypertension, coronary artery disease. Allergies: none. Which medication discrepancy should the pharmacist address first?
   Answer: Clarify and correct the metoprolol formulation and dosing (succinate once daily vs tartrate twice daily) to prevent excessive beta-blockade This question tests the ability to identify and prioritize medication discrepancies during reconciliation that could cause immediate patient harm. The patient presents with symptomatic bradycardia (HR 44 bpm) and near-syncope, with a critical discrepancy between metoprolol formulations - the pharmacy shows extended-release succinate once daily while the cardiologist prescribed immediate-release tartrate twice daily, and the patient is taking two doses daily. Clarifying and correcting the metoprolol formulation and dosing (option A) is the highest priority because the patient may be taking double the intended dose or mixing formulations, leading to excessive beta-blockade and symptomatic bradycardia. Discontinuing atorvastatin (option B) is inappropriate as statins don't cause dizziness and are essential for coronary artery disease management. Increasing hydrochlorothiazide (option C) could worsen orthostatic symptoms and isn't indicated with bradycardia present. Adding ibuprofen (option D) would not address the underlying cause and could interact with aspirin. When conducting medication reconciliation, always prioritize discrepancies that could cause immediate harm, particularly with high-risk medications like beta-blockers where formulation differences significantly impact dosing frequency and clinical effects.
6. A 48-year-old female (70 kg) with epilepsy presents for refill synchronization. The pharmacy profile lists lamotrigine 200 mg by mouth twice daily. The patient reports her neurologist recently increased it to 300 mg twice daily, but she has been alternating doses because she is running out early. Current meds: lamotrigine as above, folic acid 1 mg daily, and an OTC "energy" supplement containing caffeine. Medical history: epilepsy. Allergies: none. Labs: AST 22 U/L, ALT 25 U/L, SCr 0.8 mg/dL. Which medication discrepancy should the pharmacist address first?
   Answer: Verify the intended lamotrigine dose with the prescriber and update the medication list to prevent subtherapeutic dosing and seizures This question tests the resolution of dosing discrepancies in antiepileptic therapy during refill reconciliation. The key patient-specific factor is the unreconciled lamotrigine dose increase, leading to alternating and potential subtherapeutic levels. Verifying and updating the dose is the best choice to prevent seizures and ensure adherence. Stopping folic acid is unnecessary as it is beneficial; doubling caffeine is inappropriate; removing from profile ignores the issue. A transferable clinical pearl is to titrate lamotrigine slowly to minimize rash risk. Best practices include prescriber verification for dose changes and synchronizing refills.
7. A 34-year-old female (60 kg) is picking up a new prescription for trimethoprim-sulfamethoxazole (TMP-SMX) DS 1 tablet by mouth twice daily for 7 days for a skin infection. Her profile lists a documented allergy: "sulfa—anaphylaxis." Current medications: sertraline 50 mg daily, ethinyl estradiol/levonorgestrel 1 tablet daily, and acetaminophen as needed. Medical history: depression. Labs: SCr 0.8 mg/dL, AST/ALT within normal limits. Which medication should be discontinued based on the patient's allergy?
   Answer: Trimethoprim-sulfamethoxazole DS 1 tablet by mouth twice daily This question tests the recognition of contraindications based on documented allergies during medication dispensing and reconciliation. The key patient-specific factor is the patient's anaphylactic allergy to sulfa drugs, making trimethoprim-sulfamethoxazole (TMP-SMX) inappropriate due to the sulfonamide component. Discontinuing TMP-SMX is the best choice to prevent a severe allergic reaction while treating the infection with an alternative. Sertraline, ethinyl estradiol/levonorgestrel, and acetaminophen are not sulfa-related and pose no allergy risk in this context. A transferable clinical pearl is to always verify allergy details and cross-reactivities before dispensing high-risk medications. Best practices for medication reconciliation include updating allergy profiles and consulting prescribers for alternatives when contraindications are identified.
8. A 62-year-old male (86 kg) is admitted for elective surgery. His medication history shows rivaroxaban 20 mg by mouth daily for atrial fibrillation, but the patient states he was switched to apixaban 5 mg by mouth twice daily by his cardiologist last month and has been taking both "to be safe." OTC: fish oil 1000 mg daily. Medical history: atrial fibrillation. Allergies: none. Labs: SCr 1.0 mg/dL, hemoglobin 11.5 g/dL (low). What is the most significant duplication in therapy present?
   Answer: Rivaroxaban and apixaban (both direct oral anticoagulants) taken together This question tests the identification of anticoagulant duplications during pre-surgical medication reconciliation. The key patient-specific factor is the concurrent rivaroxaban and apixaban, both DOACs, increasing bleeding risk as shown by low hemoglobin. This duplication is most significant because it represents overdose potential. Apixaban or rivaroxaban with fish oil may slightly increase bleeding but is less critical; dual use does not improve efficacy and heightens risk. A transferable clinical pearl is to ensure complete transitions when switching DOACs to avoid overlaps. Best practices include patient confirmation of current use and holding anticoagulants pre-surgery.
9. A 72-year-old female (weight 60 kg) is seen in a community pharmacy 2 days after hospital discharge for heart failure exacerbation. Discharge medications: sacubitril/valsartan 24/26 mg twice daily, carvedilol 12.5 mg twice daily, furosemide 40 mg once daily, spironolactone 25 mg once daily, and potassium chloride 20 mEq once daily. Her pre-admission home list (still in her pill organizer) includes lisinopril 20 mg once daily, which she asks if she should continue "with the new heart pill." Labs from discharge: serum creatinine 1.1 mg/dL, potassium 4.8 mEq/L, alanine aminotransferase 25 U/L. Medical history: heart failure with reduced ejection fraction, hypertension. Allergies: none. What adjustment is needed for this patient's medication therapy post-discharge?
   Answer: Discontinue lisinopril 20 mg once daily and ensure appropriate washout before starting/continuing sacubitril/valsartan This question evaluates understanding of contraindicated drug combinations in heart failure management during post-discharge medication reconciliation. The patient was discharged on sacubitril/valsartan (an ARNI - angiotensin receptor-neprilysin inhibitor) but still has lisinopril (an ACE inhibitor) in her pill organizer from pre-admission, creating a dangerous drug interaction risk. Discontinuing lisinopril and ensuring appropriate washout before continuing sacubitril/valsartan (option B) is essential because concurrent use of ACE inhibitors with ARNIs is contraindicated due to significantly increased risk of angioedema - a 36-hour washout period is required when switching from ACE inhibitor to ARNI. Continuing both medications together (option A) is contraindicated and dangerous. Stopping carvedilol (option C) is inappropriate as beta-blockers are cornerstone therapy in HFrEF. Increasing potassium (option D) is not indicated with current potassium of 4.8 mEq/L and concurrent spironolactone use. Post-discharge medication reconciliation is critical for preventing readmissions and adverse events, particularly when therapy changes involve contraindicated combinations that patients might not recognize if using old pill supplies.
10. A 70-year-old male (weight 80 kg) is seen in a primary care clinic for fatigue and nausea. His medication list includes digoxin 0.25 mg once daily, furosemide 40 mg once daily, lisinopril 10 mg once daily, and OTC senna as needed. Labs today: serum creatinine 1.9 mg/dL (elevated; baseline 1.1), potassium 3.1 mEq/L (low), alanine aminotransferase 30 U/L; heart rate 52 beats/min. Medical history: heart failure, atrial fibrillation. Allergies: none. Which medication discrepancy should the pharmacist address first?
    Answer: Evaluate digoxin dosing and possible toxicity risk given renal function decline and hypokalemia This question tests the ability to recognize signs of digoxin toxicity and prioritize interventions during medication reconciliation in a patient with worsening renal function. The patient presents with classic signs of digoxin toxicity including nausea, fatigue, and bradycardia (HR 52 bpm), with significant risk factors including declined renal function (SCr increased from 1.1 to 1.9 mg/dL) and hypokalemia (K+ 3.1 mEq/L). Evaluating digoxin dosing and possible toxicity risk (option B) is the highest priority because digoxin has a narrow therapeutic index, is renally eliminated, and toxicity risk increases substantially with declining kidney function and hypokalemia - the current dose likely needs reduction or temporary discontinuation. Increasing senna use (option A) would not treat nausea and is inappropriate. Adding calcium carbonate (option C) for fatigue doesn't address the underlying cause. Discontinuing lisinopril (option D) is incorrect as ACE inhibitors cause hyperkalemia, not hypokalemia - the low potassium is likely from furosemide. When conducting medication reconciliation in patients with changing renal function, always reassess dosing of renally-eliminated drugs with narrow therapeutic indices, particularly digoxin where toxicity can be life-threatening.
11. A 58-year-old female (weight 70 kg) is at the anticoagulation clinic for warfarin follow-up due to atrial fibrillation. Current medications: warfarin 5 mg once daily, metoprolol succinate 100 mg once daily, metformin 1000 mg twice daily, and a new OTC product she started 10 days ago for "joint health" (glucosamine/chondroitin). She also reports taking OTC naproxen 220 mg twice daily for knee pain for the past week. Labs today: INR 4.6 (goal 2–3), serum creatinine 0.9 mg/dL, alanine aminotransferase 28 U/L, hemoglobin 12.8 g/dL. Medical history: atrial fibrillation, type 2 diabetes. Allergies: sulfonamide antibiotics (rash). What is the most concerning interaction in this patient's regimen?
    Answer: Warfarin plus naproxen increasing bleeding risk This question evaluates the ability to identify dangerous drug interactions during medication reconciliation in an anticoagulated patient. The patient has a significantly elevated INR of 4.6 (goal 2-3) and is taking warfarin with naproxen, which represents a major drug interaction due to increased bleeding risk through multiple mechanisms. Warfarin plus naproxen (option A) is the most concerning interaction because NSAIDs like naproxen inhibit platelet aggregation, can cause GI ulceration, and may displace warfarin from protein binding sites, all contributing to increased bleeding risk with an already supratherapeutic INR. Metformin plus metoprolol (option B) does not cause hypoglycemia or affect metformin clearance - this is a safe combination. Warfarin plus glucosamine/chondroitin (option C) may potentially increase INR in some patients but would not cause reduced anticoagulation. Metoprolol plus naproxen (option D) does not cause bradycardia through any interaction mechanism. During medication reconciliation for anticoagulated patients, always screen for NSAIDs (prescription and OTC) as they represent one of the most dangerous drug interactions with warfarin, particularly when INR is already elevated.
12. A 45-year-old male (95 kg) presents to the ED for an asthma exacerbation. He reports using his albuterol inhaler "every hour" and also taking an OTC ephedrine/guaifenesin asthma tablet product several times daily. Current prescriptions: fluticasone/salmeterol 250/50 mcg, 1 inhalation twice daily (often missed), albuterol HFA 2 puffs every 4–6 hours as needed. Medical history: asthma. Allergies: none. Labs: potassium 3.1 mEq/L (low), SCr 0.9 mg/dL. What is the most concerning interaction in this patient's regimen?
    Answer: Excess sympathomimetic use (albuterol plus OTC ephedrine) may worsen tachycardia and hypokalemia This question tests the identification of OTC sympathomimetic overuse contributing to asthma exacerbations and electrolyte imbalances. The key patient-specific factor is the excess use of albuterol and ephedrine, both beta-agonists, worsening tachycardia and hypokalemia. This interaction is most concerning because it can precipitate arrhythmias and exacerbate asthma symptoms. Fluticasone/salmeterol does not inactivate albuterol; guaifenesin does not cause bronchospasm; ephedrine does not cause adrenal crisis. A transferable clinical pearl is to limit sympathomimetic overuse in asthma to prevent tachyphylaxis and hypokalemia. Best practices include educating on OTC risks and ensuring adherence to controller therapies during reconciliation.
13. A 72-year-old male (90 kg) presents for medication reconciliation after hospital discharge for heart failure exacerbation. Discharge list includes: sacubitril/valsartan 24/26 mg by mouth twice daily (new), carvedilol 12.5 mg by mouth twice daily, furosemide 40 mg by mouth daily, spironolactone 25 mg by mouth daily, and potassium chloride 20 mEq by mouth daily. His pre-admission home meds included lisinopril 20 mg by mouth daily, which he still has at home. Medical history: HFrEF, hypertension. Allergies: none. Labs today: SCr 1.6 mg/dL, potassium 5.4 mEq/L (high). Which action should the pharmacist take to optimize this patient's medication regimen?
    Answer: Instruct the patient to stop lisinopril and contact the prescriber due to risk with sacubitril/valsartan and hyperkalemia This question tests the optimization of heart failure regimens by identifying contraindications and lab abnormalities during post-discharge reconciliation. The key patient-specific factor is the concurrent use of lisinopril and sacubitril/valsartan, which can cause severe hyperkalemia and angioedema, compounded by elevated potassium and SCr. Instructing the patient to stop lisinopril and contact the prescriber is the best choice to mitigate risks of hyperkalemia and dual renin-angiotensin inhibition. Continuing both is contraindicated and worsens hyperkalemia; holding carvedilol is suboptimal as it is essential for HFrEF; increasing potassium exacerbates hyperkalemia. A transferable clinical pearl is to avoid combining ACE inhibitors with ARNI therapy, with a mandatory 36-hour washout period. Best practices include reviewing discharge summaries against home meds and monitoring electrolytes in heart failure patients.
14. A 60-year-old male (79 kg) with benign prostatic hyperplasia (BPH) is seen for dizziness and falls. Medication list: tamsulosin 0.4 mg by mouth nightly, sildenafil 50 mg by mouth as needed, and hydrochlorothiazide 25 mg daily. He reports taking sildenafil "most nights" and sometimes takes two tablets. Medical history: BPH, hypertension. Allergies: none. Labs: blood pressure today 92/58 mmHg, SCr 1.0 mg/dL. What is the most concerning interaction in this patient's regimen?
    Answer: Tamsulosin plus frequent/high-dose sildenafil may cause symptomatic hypotension and falls This question tests the identification of hypotensive interactions in BPH and ED treatments during reconciliation. The key patient-specific factor is tamsulosin with frequent high-dose sildenafil, both alpha-blockers, causing hypotension and falls as per low BP. This interaction is most concerning due to symptomatic risks in hypertension. Hydrochlorothiazide does not cause sildenafil hyperkalemia; sildenafil does not inactivate tamsulosin; tamsulosin does not cause ototoxicity with HCTZ. A transferable clinical pearl is to limit sildenafil to 25 mg with alpha-blockers and separate dosing. Best practices include assessing frequency of PRN meds and monitoring vitals.
15. A 64-year-old female (70 kg) with type 2 diabetes comes for a comprehensive medication review. She takes metformin 1000 mg by mouth twice daily, glipizide 10 mg by mouth twice daily, and insulin glargine 20 units subcutaneously nightly. She recently started an OTC "cold and flu" product containing pseudoephedrine and dextromethorphan. Medical history: diabetes, hypertension. Allergies: none. Labs: A1c 7.9%, SCr 0.9 mg/dL, blood pressure today 168/96 mmHg. What is the most concerning interaction in this patient's regimen?
    Answer: Pseudoephedrine may increase blood pressure and counteract antihypertensive control This question tests the identification of significant drug interactions in patients with comorbidities during comprehensive medication reviews. The key patient-specific factor is the patient's hypertension and elevated blood pressure, exacerbated by pseudoephedrine's sympathomimetic effects. Pseudoephedrine increasing blood pressure is the most concerning because it directly counteracts antihypertensive control in this diabetic patient. Dextromethorphan does not cause hypoglycemia with insulin; pseudoephedrine does not reduce metformin absorption; dextromethorphan does not inactivate glipizide or cause hyperkalemia. A transferable clinical pearl is to caution patients with hypertension against OTC sympathomimetics like pseudoephedrine. Best practices for reconciliation include assessing OTC use and correlating with vital signs and labs.
16. A 63-year-old female (weight 68 kg) presents for a comprehensive medication review and brings in two inhalers that she uses daily. She reports taking fluticasone/salmeterol 250/50 mcg 1 inhalation twice daily, tiotropium 18 mcg 1 inhalation once daily, and two rescue inhalers: albuterol HFA 2 puffs every 4–6 hours as needed and levalbuterol HFA 2 puffs every 4–6 hours as needed; she states she alternates them "so they don't stop working." Labs: serum creatinine 0.9 mg/dL, alanine aminotransferase 24 U/L. Medical history: chronic obstructive pulmonary disease. Allergies: none. What is the most significant duplication in therapy present?
    Answer: Albuterol HFA plus levalbuterol HFA as duplicate short-acting beta-2 agonist therapy This question evaluates the ability to identify therapeutic duplications during comprehensive medication review, specifically focusing on inhaled bronchodilators in COPD management. The patient is using both albuterol HFA and levalbuterol HFA as rescue inhalers, which represents a clinically significant therapeutic duplication that increases adverse effect risk without additional benefit. Albuterol HFA plus levalbuterol HFA (option C) is the most significant duplication because levalbuterol is simply the R-enantiomer of albuterol - using both provides no additional bronchodilation but doubles the risk of beta-agonist side effects like tachycardia, tremor, and hypokalemia. Tiotropium plus fluticasone/salmeterol (option A) represents appropriate LAMA + ICS/LABA combination therapy for COPD. Fluticasone plus salmeterol within the combination inhaler (option B) is not a duplication but rather a fixed-dose combination product. Tiotropium plus albuterol (option D) represents appropriate LAMA plus SABA therapy with different mechanisms of action. During medication reconciliation, identifying therapeutic duplications is essential for optimizing therapy and reducing polypharmacy - patients often don't recognize when different brand names contain the same or similar active ingredients.
17. A 69-year-old male (83 kg) is discharged after an ischemic stroke. Discharge medications include: aspirin 81 mg daily, atorvastatin 80 mg nightly, and lisinopril 10 mg daily. His home medication list includes clopidogrel 75 mg daily that he has been taking for years after a coronary stent; the discharge summary does not mention it. Medical history: coronary artery disease with prior stent, hypertension, hyperlipidemia. Allergies: none. Labs: SCr 1.0 mg/dL, hemoglobin 13.2 g/dL. Which medication discrepancy should the pharmacist address first?
    Answer: Clarify whether clopidogrel should be continued or stopped to avoid unintended dual antiplatelet therapy or premature discontinuation This question tests the clarification of antithrombotic continuity post-stroke during discharge reconciliation. The key patient-specific factor is the omission of clopidogrel from the discharge list, risking either premature discontinuation or unintended dual therapy. Clarifying continuation is the best choice to align with CAD history and prevent thrombotic events. Stopping atorvastatin is incorrect as it is beneficial; increasing aspirin is unnecessary; adding vitamin E lacks evidence. A transferable clinical pearl is to evaluate DAPT duration based on stent type and timing. Best practices include reviewing prior therapies against discharge plans for omissions.
18. A 52-year-old female (68 kg) is discharged after an acute coronary syndrome with a new prescription for clopidogrel 75 mg by mouth daily. Her home medication list includes omeprazole 20 mg by mouth daily for GERD, atorvastatin 80 mg nightly, and metoprolol succinate 50 mg daily. OTC: calcium carbonate as needed. Allergies: none. Labs: AST/ALT normal, SCr 0.8 mg/dL. What is the most concerning interaction in this patient's regimen?
    Answer: Omeprazole may reduce activation of clopidogrel; consider an alternative acid-suppressing agent This question tests the recognition of pharmacokinetic drug interactions affecting antiplatelet efficacy during post-discharge reconciliation. The key patient-specific factor is omeprazole's inhibition of CYP2C19, reducing clopidogrel's activation and antithrombotic effect. Recommending an alternative acid-suppressor is the best choice to maintain clopidogrel's efficacy without compromising GERD management. Calcium carbonate does not cause clopidogrel toxicity; atorvastatin has minimal interaction; metoprolol does not increase bleeding with clopidogrel. A transferable clinical pearl is to avoid PPIs like omeprazole with clopidogrel; consider H2 blockers instead. Best practices include screening for CYP interactions in antiplatelet regimens during transitions.
19. A 74-year-old female (65 kg) is discharged after treatment for a deep vein thrombosis. Discharge prescription is apixaban 10 mg by mouth twice daily for 7 days, then 5 mg by mouth twice daily thereafter. During counseling, she states she will continue her home warfarin 5 mg daily "until the apixaban runs out" because she is afraid of clots. Medical history: prior DVT, hypertension. Allergies: none. Labs: INR 2.2 today, SCr 0.9 mg/dL. Which medication discrepancy should the pharmacist address first?
    Answer: Clarify and prevent unintended concurrent warfarin and apixaban use; contact prescriber to confirm transition plan This question tests the prevention of anticoagulant overlaps during post-DVT discharge counseling and reconciliation. The key patient-specific factor is the patient's plan for concurrent warfarin and apixaban, risking supratherapeutic anticoagulation and bleeding. Clarifying and preventing this is the best choice to ensure safe transition per guidelines. Instructing long-term combination is dangerous; reducing apixaban ignores the overlap; stopping apixaban abruptly risks thrombosis. A transferable clinical pearl is to overlap warfarin with DOACs only until INR is therapeutic during switches. Best practices include patient education on transitions and confirming understanding.
20. A 76-year-old female (58 kg) on warfarin for a mechanical heart valve comes for INR follow-up. She reports starting an OTC "high-dose vitamin K2" supplement 2 weeks ago for bone health. Current meds: warfarin 4 mg by mouth daily, amlodipine 5 mg daily, and acetaminophen as needed. Medical history: mechanical aortic valve, hypertension. Allergies: none. Labs today: INR 1.4 (low; goal 2.5–3.5), SCr 0.9 mg/dL, AST/ALT normal. Which medication discrepancy should the pharmacist address first?
    Answer: Identify the new vitamin K supplement as a cause of reduced warfarin effect and advise stopping it or maintaining consistent intake with prescriber-guided INR management This question tests the impact of dietary supplements on anticoagulant stability during INR follow-up and reconciliation. The key patient-specific factor is the new vitamin K supplement antagonizing warfarin, causing subtherapeutic INR. Identifying and advising on consistent intake or discontinuation is the best choice for INR management. Increasing amlodipine is irrelevant; stopping acetaminophen is unnecessary as it can potentiate, not antagonize; holding warfarin worsens subtherapeutic state. A transferable clinical pearl is to maintain consistent vitamin K intake and monitor INR with changes. Best practices include screening for OTC supplements and educating on dietary impacts.

Start this quiz